. . "A large development in the field of biosciences and personalized medicine is ongoing during last decade. The technologies coming along bring a more effective development of new drugs, improved diagnosis, earlier medical interventions and better therapeutical outcomes together with an effective and economical spending of the material and financial resources which are more and more limited. Examples of successful applications of personalized approach include e.g. diagnostics of mutations in genes of the EGFR pathway in colon cancer, non-small cell lung carcinoma or malignant melanoma or screening for predisposition to hereditary cancers (mutations in BRCA1 and 2, APC, MUTYH, TP53 and other genes) or obesity (dysfunction of a GPR120). Known examples of personalized approach are those explaining altered drug metabolism in case of warfarin (CYP2C9 and VKORC1 gene), clopidogrel (CYP2C19), or azathioprine (gene for TPMT). Further possibilities include finding right doses of antidepressants and antipsychotics based on CYP2D6 and CYP2C19 genotype; in near future, new genetic biomarkers are expected to be validated as e.g. UGT1A1 gene mutation leading to toxicity of irinotecan. Progress in studies on genetic basis of diseases will result in progress in personalization of medicine and pharmacotherapy."@en . . . "Perzonalizovan\u00E1 medic\u00EDna - sou\u010Dasn\u00E1 praxe a p\u0159\u00EDsliby do budoucna" . . "Klinick\u00E1 farmakologie a farmacie" . "RIV/61989592:15110/12:33140407" . "individualized therapy; molecular biology; diagnostics; pharmacogenetics; personalized medicine"@en . "Personalized medicine - anticipation of possibilities"@en . . "Perzonalizovan\u00E1 medic\u00EDna - sou\u010Dasn\u00E1 praxe a p\u0159\u00EDsliby do budoucna"@cs . "CZ - \u010Cesk\u00E1 republika" . "158372" . "2"^^ . . . "3" . . . . . . . "2"^^ . "P(ED0030/01/01), P(EE2.3.20.0019)" . . "1212-7973" . "Perzonalizovan\u00E1 medic\u00EDna - sou\u010Dasn\u00E1 praxe a p\u0159\u00EDsliby do budoucna" . "posledn\u00ED dob\u011B prob\u00EDh\u00E1 na poli biomedic\u00EDnsk\u00E9ho v\u00FDzkumu a jeho aplikac\u00ED st\u00E1le bou\u0159liv\u011Bj\u0161\u00ED v\u00FDvoj. Perzonalizovan\u00E1 medic\u00EDna znamen\u00E1 efektivn\u011Bj\u0161\u00ED v\u00FDvoj \u00FA\u010Dinn\u011Bj\u0161\u00EDch l\u00E9\u010Div, p\u0159esn\u011Bj\u0161\u00ED diagnostiku, v\u010Dasn\u011Bj\u0161\u00ED l\u00E9\u010Debn\u00E9 z\u00E1sahy a lep\u0161\u00ED terapeutick\u00E9 v\u00FDsledky, to v\u0161e ruku v ruce s efektivn\u00EDm a ekonomick\u00FDm vyu\u017E\u00EDv\u00E1n\u00EDm materi\u00E1ln\u00EDch prost\u0159edk\u016F, jejich\u017E zdroje jsou st\u00E1le v\u00EDce limitovan\u00E9. P\u0159\u00EDkladem je vyu\u017E\u00EDv\u00E1n\u00ED diagnostiky mutac\u00ED gen\u016F EGFR dr\u00E1hy pro predikci odpov\u011Bdi na l\u00E9\u010Dbu u kolorekt\u00E1ln\u00EDho karcinomu, nemalobun\u011B\u010Dn\u00E9ho karcinomu plic nebo malign\u00EDho melanomu \u010Di vyhled\u00E1v\u00E1n\u00ED pacient\u016F s mutacemi gen\u016F predisponuj\u00EDc\u00EDch nosi\u010De k n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm (nap\u0159. geny BRCA1 a BRCA2, APC, MUTYH, TP53 a dal\u0161\u00ED), \u010Di s dysfunkc\u00ED genu GPR120 s predispozic\u00ED k obezit\u011B. Defektn\u00ED alely gen\u016F k\u00F3duj\u00EDc\u00EDch enzymy metabolizmu l\u00E9\u010Div maj\u00ED klinick\u00FD v\u00FDznam u terapie nap\u0159. warfarinem (p\u0159edev\u0161\u00EDm geny pro CYP2C9 a VKORC1), klopidogrelem (CYP2C19), azathioprinem (gen pro TPMT), n\u011Bkter\u00FDmi antidepresivy a antipsychotiky (CYP2D6 a CYP2C19). Dal\u0161\u00ED markery, nap\u0159. genotyp UGT1A1 (mutace vede ke zv\u00FD\u0161en\u00E9 toxicit\u011B irinotekanu), jsou ve stadiu validace. Nen\u00ED pochyb o tom, \u017Ee rozvoj pozn\u00E1n\u00ED povede k pokroku v perzonalizaci medic\u00EDny a farmakoterapie zejm\u00E9na." . "Anzenbacher, Pavel" . "RIV/61989592:15110/12:33140407!RIV13-MSM-15110___" . "Personalized medicine - anticipation of possibilities"@en . "Nekvindov\u00E1, Jana" . . . "Perzonalizovan\u00E1 medic\u00EDna - sou\u010Dasn\u00E1 praxe a p\u0159\u00EDsliby do budoucna"@cs . "posledn\u00ED dob\u011B prob\u00EDh\u00E1 na poli biomedic\u00EDnsk\u00E9ho v\u00FDzkumu a jeho aplikac\u00ED st\u00E1le bou\u0159liv\u011Bj\u0161\u00ED v\u00FDvoj. Perzonalizovan\u00E1 medic\u00EDna znamen\u00E1 efektivn\u011Bj\u0161\u00ED v\u00FDvoj \u00FA\u010Dinn\u011Bj\u0161\u00EDch l\u00E9\u010Div, p\u0159esn\u011Bj\u0161\u00ED diagnostiku, v\u010Dasn\u011Bj\u0161\u00ED l\u00E9\u010Debn\u00E9 z\u00E1sahy a lep\u0161\u00ED terapeutick\u00E9 v\u00FDsledky, to v\u0161e ruku v ruce s efektivn\u00EDm a ekonomick\u00FDm vyu\u017E\u00EDv\u00E1n\u00EDm materi\u00E1ln\u00EDch prost\u0159edk\u016F, jejich\u017E zdroje jsou st\u00E1le v\u00EDce limitovan\u00E9. P\u0159\u00EDkladem je vyu\u017E\u00EDv\u00E1n\u00ED diagnostiky mutac\u00ED gen\u016F EGFR dr\u00E1hy pro predikci odpov\u011Bdi na l\u00E9\u010Dbu u kolorekt\u00E1ln\u00EDho karcinomu, nemalobun\u011B\u010Dn\u00E9ho karcinomu plic nebo malign\u00EDho melanomu \u010Di vyhled\u00E1v\u00E1n\u00ED pacient\u016F s mutacemi gen\u016F predisponuj\u00EDc\u00EDch nosi\u010De k n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm (nap\u0159. geny BRCA1 a BRCA2, APC, MUTYH, TP53 a dal\u0161\u00ED), \u010Di s dysfunkc\u00ED genu GPR120 s predispozic\u00ED k obezit\u011B. Defektn\u00ED alely gen\u016F k\u00F3duj\u00EDc\u00EDch enzymy metabolizmu l\u00E9\u010Div maj\u00ED klinick\u00FD v\u00FDznam u terapie nap\u0159. warfarinem (p\u0159edev\u0161\u00EDm geny pro CYP2C9 a VKORC1), klopidogrelem (CYP2C19), azathioprinem (gen pro TPMT), n\u011Bkter\u00FDmi antidepresivy a antipsychotiky (CYP2D6 a CYP2C19). Dal\u0161\u00ED markery, nap\u0159. genotyp UGT1A1 (mutace vede ke zv\u00FD\u0161en\u00E9 toxicit\u011B irinotekanu), jsou ve stadiu validace. Nen\u00ED pochyb o tom, \u017Ee rozvoj pozn\u00E1n\u00ED povede k pokroku v perzonalizaci medic\u00EDny a farmakoterapie zejm\u00E9na."@cs . . . . "26" . "3"^^ . "[59929F692615]" . "15110" .